+Vote!
Medical News Today (Free subscription) | 12/11/2008
Boston Scientific Corporation (NYSE: BSX) today announced that it has received approval from the U.S. Food and Drug Administration to market its Apex™ PTCA(1) Dilatation Catheter. The Apex Catheter is a high-performance pre-dilatation balloon catheter developed specifically to address physicians' needs in treating the most challenging atherosclerotic lesions. It is available for distribution...
+Vote!
PR News Wire (Free subscription) | 12/11/2008
CLEVELAND, Nov. 12 /PRNewswire/ -- Intelect Medical, Inc., an early
stage company developing an implantable neuromodulation system for stroke
and traumatic brain injury recovery, announced it has closed a licensing
and financing deal, led by existing investor Boston Scientific Corporation
(NYSE: ). Existing investor, Greatbatch, Inc. (NYSE: ), also
participated in the equity portion of...
+Vote!
Life Science World (Free subscription) | 10/11/2008
[NEWS] New design provides more options for treating patients with complex lesions NATICK, Mass., Nov. 10 /PRNewswire-FirstCall/ — Boston Scientific Corporation (NYSE: BSX) today announced that it has received approval from the U.S. Food and Drug Administration to market its Apex™ PTCA Dilatation Catheter. The Apex Catheter is a high-performance pre-dilatation balloon catheter developed...
+Vote!
Medical News Today (Free subscription) | 07/11/2008
Boston Scientific Corporation (NYSE: BSX) today announced that the first patient was enrolled in the SEPTAL CRT clinical study, sponsored by the Company's Cardiac Rhythm Management (CRM) group. The patient was enrolled in France by Prof. Christophe Leclercq MD from CHU-Hôpital Pontchaillou, Rennes.
+Vote!
PR News Wire (Free subscription) | 10/11/2008
New design provides more options for treating patients with complex lesions
NATICK, Mass., Nov. 10 /PRNewswire-FirstCall/ -- Boston Scientific
Corporation (NYSE: ) today announced that it has received approval from
the U.S. Food and Drug Administration to market its Apex(TM) PTCA(1)
Dilatation Catheter. The Apex Catheter is a high-performance pre-dilatation
balloon catheter developed...
+Vote!
Red Orbit (Free subscription) | 29/10/2008
NATICK, Mass., Oct. 29 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today welcomed passage of legislation to help active members of the U.S. armed forces and service veterans better manage the challenges of chronic pain.
+Vote!
PR News Wire (Free subscription) | 29/10/2008
NATICK, Mass., Oct. 29 /PRNewswire-FirstCall/ -- Boston Scientific
Corporation (NYSE: ) today welcomed passage of legislation to help
active members of the U.S. armed forces and service veterans better manage
the challenges of chronic pain.
The Military Pain Care Act of 2008 was included in the National Defense
Authorization Act, recently passed by Congress and signed into law by the
President....
+Vote!
Red Orbit (Free subscription) | 24/10/2008
NATICK, Mass., Oct. 23 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today announced that the U.S.
+Vote!
PR News Wire (Free subscription) | 23/10/2008
Leading carotid stent in Europe and other international markets now
available in the United States
NATICK, Mass., Oct. 23 /PRNewswire-FirstCall/ -- Boston Scientific
Corporation (NYSE: ) today announced that the U.S. Food and Drug
Administration (FDA) has approved its Carotid WALLSTENT(R) Monorail(R)
Endoprosthesis for the treatment of patients with carotid artery disease
who are at...
+Vote!
Business Wire (Free subscription) | 23/10/2008
BUFORD, Ga.--(BUSINESS WIRE)--Theragenics Corporation (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced the hiring of
+Vote!
Seeking Alpha China (Free subscription) | 21/10/2008
Boston Scientific Corporation (BSX) is scheduled to report Q3 earnings before market open Wednesday, Oct. 22, with a conference call scheduled for 8:00 am ET. Guidance Analysts are expecting a profit of 11c on revenue of $1.97B. The consensus range for EPS is 8c to 12c, with a revenue range of $1.90B to $2.04B, according to First Call. In Q2, the company reported EPS 20c vs. consensus...
+Vote!
PR News Wire (Free subscription) | 21/10/2008
NATICK, Mass., Oct. 21 /PRNewswire-FirstCall/ -- Boston Scientific
Corporation (NYSE: ) today announced financial results for the third
quarter ended September 30, 2008, as well as guidance for net sales and
earnings per share (EPS) for the fourth quarter of 2008.
Third quarter highlights:
-- Reported net sales of $1.978 billion and adjusted EPS of $0.16
-- Maintained U.S. drug-eluting...
+Vote!
Business Wire (Free subscription) | 01/12/2008
Mooradian has extensive industry medical product development experience, as well as strong academic credentials, in cardiovascular biology and pathology. Prior to rejoining Synovis, he served as director of the Research and Technology Center within the Cardiac Rhythm Management and Neuromodulation businesses of Boston Scientific Corporation. From 2005 to 2006, he was vice president of...
+Vote!
Food and Drug Adminstration (FDA): CDRHNew (Free subscription) | 25/11/2008
APPLICATION NUMBER / DATE of APPROVALDEVICE TRADE NAMECOMPANY NAME CITY, STATE, & ZIPDEVICE DESCRIPTION / INDICATIONS10/23/08 Carotid WALLSTENT® Monorail® Endoprosthesis Boston Scientific Corporation Mountain View, CA 94043 Approval for the Carotid WALLSTENT® Monorail® Endoprosthesis. The device, used in conjunction with the Boston Scientific embolic protection system, is indicated for...
